School of Medicine

Wayne State University School of Medicine

SURPASS- Study Evaluating the Benefits of Switching Current MS Therapy (Copaxone® or Rebif®) to Tysabri®- Closed to Enrollment

This is a multi-center study which will evaluate the benefits of switching therapy from either glatiramer acetate (Copaxone ®) or interferon β-1a(Rebif ®) to Natalizumab(Tysabri ®) in patients with relapsing -remitting Multiple Sclerosis (RRMS). Patients will be randomly assigned to receive either natalizumab (300 mg IV every 4 weeks), Interferon β-1a (44 mg subcutaneous injections 3 times per week), or glatiramer acetate (20 mg subcutaneous injections once daily). The study duration is at least 48 weeks, but no longer than 96 weeks.

Eligibility: Patients must be 18-60 yrs old diagnosed with RRMS. Patients must have had evidence of disease activity (either relapse or new MRI lesions) while on treatment with either Copaxone ® or Rebif®. Patients must not have been treated with Tysabri® in the past. Patients must be able to walk at least 100 meter without aid or rest.
For more information visit: SURPASS